Historically, in difficult times such as the pandemic, rising inflation rates, interest rate hikes by central banks, including the US Federal Reserve, market volatility, and geopolitical tensions, etc., introduction of innovative drugs, seeking out-licensing transactions, rising overseas collaborations and implementation of AI in products has kept on prompting players to innovate or expand their offerings locally and internationally.
Looking ahead, the deal activity for life science companies in China seems promising and is anticipated to be robust post-2024, driven by substantial government support, funding, and ongoing regulatory reforms aimed at streamlining approval processes and promoting innovation.
